Symbols / CELZ Stock $2.24 +3.23% Creative Medical Technology Holdings, Inc.
CELZ (Stock) Chart
About
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Stock Fundamentals
Scroll to Statements| Market Cap | 8.28M | Enterprise Value | 1.10M | Income | -6.00M | Sales | 6.00K | Book/sh | 2.03 | Cash/sh | 1.95 |
| Dividend Yield | — | Payout | 0.00% | Employees | 4 | IPO | — | P/E | — | Forward P/E | -1.66 |
| PEG | — | P/S | 1380.09 | P/B | 1.10 | P/C | — | EV/EBITDA | -0.18 | EV/Sales | 182.77 |
| Quick Ratio | 25.30 | Current Ratio | 25.97 | Debt/Eq | 0.19 | LT Debt/Eq | — | EPS (ttm) | -2.52 | EPS next Y | -1.35 |
| EPS Growth | — | Revenue Growth | 0.00% | Earnings | 2026-03-20 | ROA | -53.03% | ROE | -86.47% | ROIC | — |
| Gross Margin | 63.43% | Oper. Margin | -648.59% | Profit Margin | 0.00% | Shs Outstand | 3.70M | Shs Float | 3.43M | Short Float | 9.38% |
| Short Ratio | 15.15 | Short Interest | — | 52W High | 6.25 | 52W Low | 1.50 | Beta | 1.99 | Avg Volume | 42.15K |
| Volume | 37.58K | Target Price | $20.00 | Recom | None | Prev Close | $2.17 | Price | $2.24 | Change | 3.23% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
- Analysts Expect Breakeven For Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Before Long - Yahoo Finance hu, 09 Apr 2026 07
- CreativeMed (CELZ) Volatility Analysis | Q3 2025: Profit Surprises - Best Pick - UBND thành phố Hải Phòng hu, 23 Apr 2026 00
- Two Creative Medical cell therapies gain WHO naming milestones - Stock Titan ue, 10 Feb 2026 08
- Does CreativeMed (CELZ) Stock pay reliable income | Price at $2.22, Up 3.74% - Retail Picks - Xã Vĩnh Công Sat, 28 Mar 2026 07
- Should I buy Creative Medical Technology Holdings, Inc. (CELZ) - Zacks Investment Research hu, 31 Jul 2025 07
- 79% of chronic back pain patients had reduced pain in cell therapy test - Stock Titan ue, 13 Jan 2026 08
- Creative Medical’s BioDefense initiative receives regulatory approval - Investing.com ue, 06 Jan 2026 08
- CELZ Forecast — Price Prediction for 2026. Should I Buy CELZ? - Intellectia AI ue, 03 Jun 2025 09
- New burn pit program uses AI and stem cells to study veterans’ toxic exposure - Stock Titan ue, 06 Jan 2026 08
- Creative Medical Technology Holdings, Inc. (CELZ) - Zacks Investment Research Wed, 05 Nov 2025 08
- Creative Medical (NASDAQ: CELZ) gets WHO INN 'olastrocel' for CELZ-201 cell therapy - Stock Titan ue, 02 Dec 2025 08
- Creative Medical (NASDAQ: CELZ) targets H1 2026 data from ADAPT; secures 2 U.S. patents - Stock Titan Mon, 27 Oct 2025 07
- New cell therapy for chronic back pain reaches key milestone in clinical test - Stock Titan Wed, 17 Dec 2025 08
- If You Invested $1,000 in Creative Med Technology Hldgs (CELZ) - Stock Titan Sun, 22 Mar 2026 15
- 2 U.S. Patents for ImmCelz: Creative Medical advances supercharged Treg therapy for HF and T1D - Stock Titan ue, 07 Oct 2025 07
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.01
-45.45%
|
0.01
+22.22%
|
0.01
-89.84%
|
0.09
|
| Operating Revenue |
|
0.01
-45.45%
|
0.01
+22.22%
|
0.01
-89.84%
|
0.09
|
| Cost Of Revenue |
|
0.00
-50.14%
|
0.00
+22.22%
|
0.00
-87.36%
|
0.03
|
| Reconciled Cost Of Revenue |
|
0.00
-50.14%
|
0.00
+22.22%
|
0.00
-87.36%
|
0.03
|
| Gross Profit |
|
0.00
-42.33%
|
0.01
+22.22%
|
0.01
-91.02%
|
0.06
|
| Operating Expense |
|
6.15
+6.89%
|
5.75
+2.22%
|
5.63
-45.41%
|
10.30
|
| Research And Development |
|
2.26
-5.87%
|
2.40
+21.83%
|
1.97
-68.56%
|
6.27
|
| Selling General And Administration |
|
3.76
+16.18%
|
3.24
-9.02%
|
3.56
-9.72%
|
3.94
|
| Total Expenses |
|
6.15
+6.85%
|
5.75
+2.23%
|
5.63
-45.52%
|
10.33
|
| Operating Income |
|
-6.14
-6.95%
|
-5.74
-2.20%
|
-5.62
+45.14%
|
-10.24
|
| Total Operating Income As Reported |
|
-6.14
-6.95%
|
-5.74
-2.20%
|
-5.62
+45.14%
|
-10.24
|
| EBITDA |
|
-6.02
-6.85%
|
-5.63
-1.95%
|
-5.53
+45.57%
|
-10.15
|
| Normalized EBITDA |
|
-6.02
-6.85%
|
-5.63
-1.95%
|
-5.53
+45.57%
|
-10.15
|
| Reconciled Depreciation |
|
0.12
+11.66%
|
0.11
+16.78%
|
0.09
+2.71%
|
0.09
|
| EBIT |
|
-6.14
-6.95%
|
-5.74
-2.20%
|
-5.62
+45.14%
|
-10.24
|
| Total Unusual Items |
|
—
|
—
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-6.00
-9.13%
|
-5.49
-3.91%
|
-5.29
+47.88%
|
-10.14
|
| Pretax Income |
|
-6.00
-9.13%
|
-5.49
-3.91%
|
-5.29
+47.88%
|
-10.14
|
| Net Non Operating Interest Income Expense |
|
0.15
-40.97%
|
0.25
-24.94%
|
0.33
+232.47%
|
0.10
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
0.00
|
| Net Interest Income |
|
0.15
-40.97%
|
0.25
-24.94%
|
0.33
+232.47%
|
0.10
|
| Interest Expense |
|
—
|
—
|
—
|
0.00
|
| Interest Income Non Operating |
|
0.15
-40.97%
|
0.25
-24.94%
|
0.33
+232.47%
|
0.10
|
| Interest Income |
|
0.15
-40.97%
|
0.25
-24.94%
|
0.33
+232.47%
|
0.10
|
| Other Income Expense |
|
—
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
—
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-6.00
-9.13%
|
-5.49
-3.91%
|
-5.29
+47.88%
|
-10.14
|
| Net Income From Continuing Operation Net Minority Interest |
|
-6.00
-9.13%
|
-5.49
-3.91%
|
-5.29
+47.88%
|
-10.14
|
| Net Income From Continuing And Discontinued Operation |
|
-6.00
-9.13%
|
-5.49
-3.91%
|
-5.29
+47.88%
|
-10.14
|
| Net Income Continuous Operations |
|
-6.00
-9.13%
|
-5.49
-3.91%
|
-5.29
+47.88%
|
-10.14
|
| Normalized Income |
|
-6.00
-9.13%
|
-5.49
-3.91%
|
-5.29
+47.88%
|
-10.14
|
| Net Income Common Stockholders |
|
-6.00
-9.13%
|
-5.49
-3.91%
|
-5.29
+47.88%
|
-10.14
|
| Diluted EPS |
|
—
|
-3.71
+1.33%
|
-3.76
+59.48%
|
-9.28
|
| Basic EPS |
|
—
|
-3.71
+1.33%
|
-3.76
+59.48%
|
-9.28
|
| Basic Average Shares |
|
—
|
1.48
+5.17%
|
1.41
+28.76%
|
1.09
|
| Diluted Average Shares |
|
—
|
1.48
+5.17%
|
1.41
+28.76%
|
1.09
|
| Diluted NI Availto Com Stockholders |
|
-6.00
-9.13%
|
-5.49
-3.91%
|
-5.29
+47.88%
|
-10.14
|
| Amortization |
|
0.12
+11.66%
|
0.11
+16.78%
|
0.09
+2.71%
|
0.09
|
| Amortization Of Intangibles Income Statement |
|
0.12
+11.66%
|
0.11
+16.78%
|
0.09
+2.71%
|
0.09
|
| Depreciation Amortization Depletion Income Statement |
|
0.12
+11.66%
|
0.11
+16.78%
|
0.09
+2.71%
|
0.09
|
| Depreciation And Amortization In Income Statement |
|
0.12
+11.66%
|
0.11
+16.78%
|
0.09
+2.71%
|
0.09
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets |
|
7.81
+17.10%
|
6.67
-37.76%
|
10.72
|
| Current Assets |
|
7.40
+20.60%
|
6.14
-40.27%
|
10.27
|
| Cash Cash Equivalents And Short Term Investments |
|
7.21
+21.34%
|
5.94
-40.52%
|
9.99
|
| Cash And Cash Equivalents |
|
7.21
+21.34%
|
5.94
+71.35%
|
3.47
|
| Cash Equivalents |
|
—
|
—
|
—
|
| Cash Financial |
|
7.21
+21.34%
|
5.94
+71.35%
|
3.47
|
| Other Short Term Investments |
|
—
|
0.00
-100.00%
|
6.52
|
| Receivables |
|
0.05
|
0.00
|
—
|
| Accounts Receivable |
|
—
|
—
|
—
|
| Inventory |
|
0.00
-100.00%
|
0.00
-66.73%
|
0.01
|
| Prepaid Assets |
|
—
|
—
|
—
|
| Other Current Assets |
|
0.14
-27.97%
|
0.19
-30.49%
|
0.28
|
| Total Non Current Assets |
|
0.41
-23.10%
|
0.53
+20.16%
|
0.44
|
| Goodwill And Other Intangible Assets |
|
0.41
-23.25%
|
0.53
+20.31%
|
0.44
|
| Other Intangible Assets |
|
0.41
-23.25%
|
0.53
+20.31%
|
0.44
|
| Other Non Current Assets |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Total Liabilities Net Minority Interest |
|
0.28
-13.05%
|
0.33
-11.78%
|
0.37
|
| Current Liabilities |
|
0.28
-13.05%
|
0.33
-11.78%
|
0.37
|
| Payables And Accrued Expenses |
|
0.28
-13.05%
|
0.33
-11.78%
|
0.37
|
| Payables |
|
0.28
-0.99%
|
0.29
-13.20%
|
0.33
|
| Accounts Payable |
|
0.27
-1.04%
|
0.27
-13.79%
|
0.32
|
| Current Accrued Expenses |
|
0.00
-100.00%
|
0.04
+0.00%
|
0.04
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
7.51
+18.50%
|
6.34
-38.69%
|
10.34
|
| Common Stock Equity |
|
7.51
+18.50%
|
6.34
-38.69%
|
10.34
|
| Capital Stock |
|
0.00
+79.76%
|
0.00
+22.22%
|
0.00
|
| Common Stock |
|
0.00
+79.76%
|
0.00
+22.22%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
3.70
+111.71%
|
1.75
+22.17%
|
1.43
|
| Ordinary Shares Number |
|
3.70
+111.43%
|
1.75
+27.29%
|
1.37
|
| Treasury Shares Number |
|
0.01
|
0.00
-100.00%
|
0.06
|
| Additional Paid In Capital |
|
78.11
+10.12%
|
70.93
+1.75%
|
69.71
|
| Retained Earnings |
|
-70.59
-9.28%
|
-64.59
-9.30%
|
-59.10
|
| Treasury Stock |
|
0.01
|
0.00
-100.00%
|
0.27
|
| Minority Interest |
|
0.01
|
0.00
|
—
|
| Total Equity Gross Minority Interest |
|
7.52
+18.66%
|
6.34
-38.69%
|
10.34
|
| Total Capitalization |
|
7.51
+18.50%
|
6.34
-38.69%
|
10.34
|
| Working Capital |
|
7.11
+22.50%
|
5.81
-41.33%
|
9.90
|
| Invested Capital |
|
7.51
+18.50%
|
6.34
-38.69%
|
10.34
|
| Net Tangible Assets |
|
7.11
+22.31%
|
5.81
-41.32%
|
9.90
|
| Tangible Book Value |
|
7.11
+22.31%
|
5.81
-41.32%
|
9.90
|
| Dueto Related Parties Current |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Notes Receivable |
|
0.05
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-5.86
-10.47%
|
-5.30
+33.96%
|
-8.03
-2.96%
|
-7.80
|
| Cash Flow From Continuing Operating Activities |
|
-5.86
-10.47%
|
-5.30
+33.96%
|
-8.03
-2.96%
|
-7.80
|
| Net Income From Continuing Operations |
|
-6.00
-9.13%
|
-5.49
-3.91%
|
-5.29
+47.88%
|
-10.14
|
| Depreciation Amortization Depletion |
|
0.12
+11.66%
|
0.11
+16.78%
|
0.09
+2.71%
|
0.09
|
| Amortization Cash Flow |
|
0.12
+11.66%
|
0.11
+16.78%
|
0.09
+2.71%
|
0.09
|
| Depreciation And Amortization |
|
0.12
+11.66%
|
0.11
+16.78%
|
0.09
+2.71%
|
0.09
|
| Amortization Of Intangibles |
|
0.12
+11.66%
|
0.11
+16.78%
|
0.09
+2.71%
|
0.09
|
| Other Non Cash Items |
|
-0.00
|
—
|
—
|
—
|
| Stock Based Compensation |
|
0.00
-90.49%
|
0.04
+0.00%
|
0.04
-46.69%
|
0.07
|
| Provisionand Write Offof Assets |
|
—
|
—
|
—
|
0.00
|
| Operating Gains Losses |
|
—
|
—
|
-0.03
|
—
|
| Gain Loss On Investment Securities |
|
—
|
—
|
-0.03
|
—
|
| Change In Working Capital |
|
0.01
-70.43%
|
0.05
+101.59%
|
-2.84
-229.83%
|
2.19
|
| Change In Receivables |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Changes In Account Receivables |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Change In Inventory |
|
0.00
-50.14%
|
0.00
+22.22%
|
0.00
+435.71%
|
0.00
|
| Change In Prepaid Assets |
|
0.05
-36.24%
|
0.08
-21.87%
|
0.11
+132.00%
|
-0.34
|
| Change In Payables And Accrued Expense |
|
-0.04
+2.48%
|
-0.04
+98.51%
|
-2.95
-217.02%
|
2.52
|
| Change In Accrued Expense |
|
-0.04
|
0.00
|
0.00
-100.00%
|
0.02
|
| Change In Payable |
|
-0.00
+93.52%
|
-0.04
+98.51%
|
-2.95
-217.74%
|
2.51
|
| Change In Account Payable |
|
-0.00
+93.52%
|
-0.04
+98.51%
|
-2.95
-217.74%
|
2.51
|
| Change In Other Current Liabilities |
|
0.00
|
0.00
|
—
|
—
|
| Investing Cash Flow |
|
-0.05
-100.80%
|
6.32
+83.45%
|
3.45
+134.18%
|
-10.08
|
| Cash Flow From Continuing Investing Activities |
|
-0.05
-100.80%
|
6.32
+83.45%
|
3.45
+134.18%
|
-10.08
|
| Capital Expenditure |
|
—
|
-0.20
-100.00%
|
-0.10
|
—
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
6.52
+83.92%
|
3.55
+135.18%
|
-10.08
|
| Purchase Of Investment |
|
—
|
0.00
+100.00%
|
-22.85
-126.77%
|
-10.08
|
| Sale Of Investment |
|
0.00
-100.00%
|
6.52
-75.30%
|
26.40
|
0.00
|
| Net Intangibles Purchase And Sale |
|
0.00
+100.00%
|
-0.20
-100.00%
|
-0.10
|
0.00
|
| Purchase Of Intangibles |
|
0.00
+100.00%
|
-0.20
-100.00%
|
-0.10
|
0.00
|
| Net Other Investing Changes |
|
-0.05
|
—
|
—
|
—
|
| Financing Cash Flow |
|
7.17
+393.23%
|
1.45
+636.86%
|
-0.27
-101.75%
|
15.47
|
| Cash Flow From Continuing Financing Activities |
|
7.17
+393.23%
|
1.45
+636.86%
|
-0.27
-101.75%
|
15.47
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
7.16
+392.57%
|
1.45
+636.82%
|
-0.27
-101.75%
|
15.47
|
| Common Stock Payments |
|
-0.01
+94.28%
|
-0.17
+35.43%
|
-0.27
|
0.00
|
| Repurchase Of Capital Stock |
|
-0.01
+94.28%
|
-0.17
+35.43%
|
-0.27
|
0.00
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Net Other Financing Charges |
|
0.01
|
—
|
—
|
—
|
| Changes In Cash |
|
1.27
-48.75%
|
2.47
+150.96%
|
-4.85
-101.95%
|
-2.40
|
| Beginning Cash Position |
|
5.94
+71.35%
|
3.47
-58.33%
|
8.32
-22.41%
|
10.72
|
| End Cash Position |
|
7.21
+21.34%
|
5.94
+71.35%
|
3.47
-58.33%
|
8.32
|
| Free Cash Flow |
|
-5.86
-6.46%
|
-5.50
+32.32%
|
-8.13
-4.24%
|
-7.80
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
7.17
+340.30%
|
1.63
|
0.00
-100.00%
|
15.47
|
| Issuance Of Capital Stock |
|
7.17
+340.27%
|
1.63
|
0.00
-100.00%
|
15.47
|
| Net Preferred Stock Issuance |
|
0.00
-100.00%
|
0.00
|
0.00
|
0.00
|
| Preferred Stock Issuance |
|
0.00
-100.00%
|
0.00
|
0.00
|
0.00
|
| Preferred Stock Payments |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-20 View
- 8-K2025-12-31 View
- 8-K2025-12-19 View
- 8-K2025-11-12 View
- 10-Q2025-11-07 View
- 8-K2025-10-31 View
- 10-Q2025-08-08 View
- 10-Q2025-05-09 View
- 8-K2025-05-06 View
- 8-K2025-04-11 View
- 8-K2025-03-14 View
- 10-K2025-03-14 View
- 8-K2025-03-07 View
- 42025-02-20 View
- 8-K2024-12-26 View
- 10-Q2024-11-08 View
- 8-K2024-10-23 View
- 10-Q2024-08-09 View
- 8-K2024-07-25 View
- 8-K2024-05-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|